Lídia Robert

13.0k total citations · 3 hit papers
26 papers, 3.7k citations indexed

About

Lídia Robert is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lídia Robert has authored 26 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Oncology and 10 papers in Immunology. Recurrent topics in Lídia Robert's work include Melanoma and MAPK Pathways (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (9 papers). Lídia Robert is often cited by papers focused on Melanoma and MAPK Pathways (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (9 papers). Lídia Robert collaborates with scholars based in United States, Canada and Spain. Lídia Robert's co-authors include Antoni Ribas, Thomas G. Graeber, Jennifer Tsoi, Blanca Homet Moreno, Siwen Hu‐Lieskovan, Richard C. Koya, Stephen Mok, Deborah J. Wong, Begoña Comı́n-Anduix and Mohammad Atefi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Lídia Robert

26 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

2018 583 citations Jennifer Tsoi, Lídia Robert et al. Cancer Cell profile →
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma

2015 435 citations Siwen Hu‐Lieskovan, Stephen Mok et al. Science Translational Medicine profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Judith M. Müller, Oscar Krijgsman et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lídia Robert United States	20	2.0k	2.0k	1.3k	544	529	26	3.7k
María Romina Girotti Argentina	21	1.6k 0.8×	1.4k 0.7×	827 0.6×	628 1.2×	302 0.6×	44	3.0k
Laura Soucek Spain	32	3.7k 1.8×	1.7k 0.9×	855 0.6×	858 1.6×	305 0.6×	54	5.0k
David Dankort Canada	25	2.6k 1.3×	2.0k 1.0×	567 0.4×	581 1.1×	318 0.6×	39	3.9k
Deric L. Wheeler United States	37	2.5k 1.2×	2.5k 1.3×	620 0.5×	751 1.4×	1.3k 2.4×	89	4.8k
Kristel Kemper Netherlands	23	2.7k 1.4×	2.9k 1.5×	630 0.5×	1.1k 2.0×	329 0.6×	35	4.7k
Mari Iida United States	30	1.5k 0.7×	1.3k 0.7×	456 0.3×	429 0.8×	620 1.2×	62	2.8k
Eugene Tulchinsky United Kingdom	31	2.8k 1.4×	1.3k 0.7×	604 0.5×	1.1k 2.1×	403 0.8×	49	3.7k
Lamorna Brown Swigart United States	28	3.4k 1.7×	2.5k 1.3×	1.0k 0.8×	1.1k 2.0×	336 0.6×	81	5.1k
Violeta Sánchez United States	28	2.1k 1.1×	2.1k 1.1×	601 0.5×	840 1.5×	661 1.2×	59	3.8k
Carla P. Martins United Kingdom	19	2.0k 1.0×	1.4k 0.7×	531 0.4×	611 1.1×	252 0.5×	25	3.1k

Countries citing papers authored by Lídia Robert

Since Specialization

Citations

This map shows the geographic impact of Lídia Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lídia Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lídia Robert more than expected).

Fields of papers citing papers by Lídia Robert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lídia Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lídia Robert. The network helps show where Lídia Robert may publish in the future.

Co-authorship network of co-authors of Lídia Robert

This figure shows the co-authorship network connecting the top 25 collaborators of Lídia Robert. A scholar is included among the top collaborators of Lídia Robert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lídia Robert. Lídia Robert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Peter, Peter Savas, Enrique Espinosa, et al.. (2021). Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Research. 81(4_Supplement). PS12–28. 9 indexed citations

Su, Yapeng, Marcus Bintz, Lídia Robert, et al.. (2019). Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance. PLoS Computational Biology. 15(6). e1007034–e1007034. 33 indexed citations

Mehta, Arnav, Yeon Joo Kim, Lídia Robert, et al.. (2018). Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discovery. 8(8). 935–943. 122 indexed citations

Tsoi, Jennifer, Lídia Robert, Kim H.T. Paraiso, et al.. (2018). Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 33(5). 890–904.e5. 583 indexed citations breakdown →

Caenepeel, Sean, Keegan S. Cooke, Guo N. Huang, et al.. (2017). MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget. 8(11). 17795–17809. 33 indexed citations

Moreno, Blanca Homet, Jesse M. Zaretsky, Ángel García-Díaz, et al.. (2016). Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research. 4(10). 845–857. 104 indexed citations

Robert, Lídia, Antoni Ribas, & Siwen Hu‐Lieskovan. (2016). Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology. 28(1). 73–80. 50 indexed citations

Hu‐Lieskovan, Siwen, Stephen Mok, Blanca Homet Moreno, et al.. (2015). Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma. Science Translational Medicine. 7(279). 279ra41–279ra41. 435 indexed citations breakdown →

Moreno, Blanca Homet, Giulia Parisi, Lídia Robert, & Antoni Ribas. (2015). Anti–PD-1 Therapy in Melanoma. Seminars in Oncology. 42(3). 466–473. 35 indexed citations

10.

Robert, Lídia, et al.. (2015). Abstract 2682: Melanoma phenotype switching to adapt to BRAF inhibition. Cancer Research. 75(15_Supplement). 2682–2682. 1 indexed citations

11.

Atefi, Mohammad, Earl Avramis, Amanda Lassen, et al.. (2014). Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research. 20(13). 3446–3457. 285 indexed citations

12.

Robert, Lídia, Jennifer Tsoi, Xiaoyan Wang, et al.. (2014). CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clinical Cancer Research. 20(9). 2424–2432. 280 indexed citations

13.

Wong, Deborah J., Lídia Robert, Mohammad Atefi, et al.. (2014). Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer. 13(1). 194–194. 85 indexed citations

14.

Lassen, Amanda, Mohammad Atefi, Lídia Robert, et al.. (2014). Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Molecular Cancer. 13(1). 83–83. 66 indexed citations

15.

Robert, Lídia, Christina L. Harview, Ryan Emerson, et al.. (2014). Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. OncoImmunology. 3(6). e29244–e29244. 66 indexed citations

16.

Müller, Judith M., Oscar Krijgsman, Jennifer Tsoi, et al.. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Communications. 5(1). 5712–5712. 427 indexed citations breakdown →

17.

Robert, Lídia, Christina L. Harview, Ryan Emerson, et al.. (2014). Abstract 5015: TCR usage analysis in blood reveals different mechanisms of action of CTLA-4 and PD-1 blockade in patients. Cancer Research. 74(19_Supplement). 5015–5015. 1 indexed citations

18.

Hu‐Lieskovan, Siwen, Lídia Robert, Blanca Homet Moreno, & Antoni Ribas. (2014). Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges. Journal of Clinical Oncology. 32(21). 2248–2254. 151 indexed citations

19.

Mok, Stephen, Richard C. Koya, Christopher Tsui, et al.. (2013). Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Research. 74(1). 153–161. 252 indexed citations

20.

Robert, Lídia. (2000). Molecular mechanisms regulating myogenic determination and differentiation. Frontiers in bioscience. 5(1). d750–d750. 312 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact